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Abstract
Background: Coronary artery disease (CAD) continues to be one of the top public health burden. Perfusion
cardiovascular magnetic resonance (CMR) is generally accepted to detect CAD, while data on its cost effectiveness
are scarce. Therefore, the goal of the study was to compare the costs of a CMR-guided strategy vs two invasive
strategies in a large CMR registry.
Methods: In 3’647 patients with suspected CAD of the EuroCMR-registry (59 centers/18 countries) costs were
calculated for diagnostic examinations (CMR, X-ray coronary angiography (CXA) with/without FFR),
revascularizations, and complications during a 1-year follow-up. Patients with ischemia-positive CMR underwent
an invasive CXA and revascularization at the discretion of the treating physician (=CMR + CXA-strategy). In the
hypothetical invasive arm, costs were calculated for an initial CXA and a FFR in vessels with ≥50 % stenoses (=CXA +
FFR-strategy) and the same proportion of revascularizations and complications were applied as in the CMR + CXA-
strategy. In the CXA-only strategy, costs included those for CXA and for revascularizations of all ≥50 % stenoses. To
calculate the proportion of patients with ≥50 % stenoses, the stenosis-FFR relationship from the literature was used.
Costs of the three strategies were determined based on a third payer perspective in 4 healthcare systems.
Results: Revascularizations were performed in 6.2 %, 4.5 %, and 12.9 % of all patients, patients with atypical chest pain
(n = 1’786), and typical angina (n = 582), respectively; whereas complications (=all-cause death and non-fatal infarction)
occurred in 1.3 %, 1.1 %, and 1.5 %, respectively. The CMR + CXA-strategy reduced costs by 14 %, 34 %, 27 %, and 24 %
in the German, UK, Swiss, and US context, respectively, when compared to the CXA + FFR-strategy; and by 59 %, 52 %,
61 % and 71 %, respectively, versus the CXA-only strategy. In patients with typical angina, cost savings by CMR + CXA
vs CXA + FFR were minimal in the German (2.3 %), intermediate in the US and Swiss (11.6 % and 12.8 %, respectively),
and remained substantial in the UK (18.9 %) systems. Sensitivity analyses proved the robustness of results.
Conclusions: A CMR + CXA-strategy for patients with suspected CAD provides substantial cost reduction compared to
a hypothetical CXA + FFR-strategy in patients with low to intermediate disease prevalence. However, in the subgroup
of patients with typical angina, cost savings were only minimal to moderate.
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Background
Coronary artery disease (CAD) continues to be a major
source of public health burden particularly in industrial-
ized countries [1]. For the European Union, the esti-
mated costs for CAD management were 60 billion Euros
in 2009, of which approximately 20 billion Euros were
attributed to direct health care costs [2]. Similarly, the
total direct costs of CAD in the United States were esti-
mated to be 107 billion dollars in the same time period
[3]. Patients with myocardial ischemia benefit most from
revascularizations, as the presence of myocardial ische-
mia is a strong predictor of major adverse cardiovascular
outcomes. Accordingly, current guidelines recommend
revascularizing patients with stable CAD if substantial
myocardial ischemia is confirmed by either non-invasive
ischemia testing or fractional flow reserve (FFR) [4–7].
Fearon and coworkers demonstrated that such an FFR-,
i.e. ischemia-guided approach, was not only safe and ef-
fective in improving patient outcomes, but reduced costs
during the first year after percutaneous coronary inter-
ventions (PCI) comparing to a luminal anatomy-guided
approach [8]. Invasive CXA, particularly when combined
with FFR, is an alternative to non-invasive testing and
should be considered in intermediate to high risk pa-
tients, i.e. with an annual mortality ≥1 % according to
ESC guidelines [5]. The AHA/ACC guidelines on ische-
mic heart disease justify the use of CXA as first line test
to define the extent and severity of CAD in patients with a
high likelihood of severe disease (based on clinical assess-
ment and/or exercise ECG testing) [9]. Cardiovascular
magnetic resonance (CMR) is now well established as a
reliable and safe technique to evaluate ischemia in patients
with known or suspected CAD [10–16] and it is recom-
mended as a class I or IIa test in European and US guide-
lines for stable CAD, respectively [4–7]. However, few
data are available to estimate the potential cost savings
using the CMR-based approach [17].
Assessment of patients with suspected CAD aiming at
effective clinical decision-making needs to not only con-
sider patient factors including cardiovascular risk factor
profile, presenting sign and symptoms, but the presence
of myocardial ischemia and the coronary arterial anat-
omy. The aim of this study was to compare the costs of
a CMR-guided strategy vs two invasive strategies. The
costs of these strategies were assessed from a health care
payer perspective for the German, United Kingdom,
Swiss, and United States health care systems.
Methods
Definitions of strategies
In the CMR-based strategy (CMR + CXA, Fig. 1), only
patients positive for ischemia on CMR were referred to a
CXA examination with potential revascularization per-
formed at the discretion of the treating physician. For
the CMR + CXA strategy costs included those for the
initial CMR, for the CXA in the ischemia-positive
patients, and for revascularizations and complications
(as shown in Fig. 1). For details on cost calculations of the
strategies, see also section below (costs of the different
procedures and strategies). For comparison, a hypothetical
Fig. 1 Decision tree and outcome in the study population – CMR + CXA strategy. Diagnostic pathway, treatment, and outcomes are shown for
the CMR + CXA strategy in the 3’647 patients of the European CMR Registry. nf-MI: non-fatal MI; ab SCD: aborted SCD
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CXA+ FFR strategy was designed which starts with a
CXA examination and in case of ≥50 % stenosis in a cor-
onary artery, an FFR testing is added. In the registry popu-
lation the revascularization rate was 6.2 % and we
assumed FFR to be positive with the same proportion in
the CXA + FFR strategy. Extrapolating from the correl-
ation between FFR and diameter stenosis from the litera-
ture [18, 19], and assuming 6.2 % positive FFR tests
(FFR ≤ 0.80) we calculate that approximately 35 %
coronary arteries have ≥50 % diameter stenosis (for for-
mulas see Additional file 1). Accordingly, 35 % of patients
were assumed to undergo FFR testing to yield 6.2 %
ischemia positive findings (Fig. 2). We applied the annual
hard event rate observed from the European CMR regis-
try, 0.38 % annually of cardiac death and non-fatal MI, to
both the CMR +CXA and CXA+ FFR strategies. This
assumption is supported by strong evidence that both,
FFR [20–22] and CMR [23–25] provide accurate prognos-
tic information at a similar level. We also calculated the
costs for a third CXA-only strategy (Fig. 3) which includes
costs for the initial CXA and those for revascularizations
in all patients with ≥50 % coronary stenoses as described
by Moschetti and coworkers [19]. Finally, these calcula-
tions were also performed for the 2 sub-groups of patients
with typical angina and atypical chest pain.
Patient population
Data from the European CMR registry were used for this
analysis [24]. The prospective “Suspected CAD” cohort
aims to assess the prognostic value of CMR in a clinical
routine setting by collecting data on subsequent treat-
ment and major adverse cardiac events (MACE) during
a follow-up of 1 year after the CMR examination [26].
The primary combined end-point of MACE included
all-cause death, aborted sudden cardiac death (SCD),
non-fatal MI, and stroke. The protocol was approved by
the ethics committee at each participating institution
and all study participants provided written informed
consent. The present analysis includes 3’647 patients
with suspected CAD who underwent CMR for ischemia
testing and for whom the one-year follow-up was com-
pleted (Table 1). For ischemia testing, a first-pass perfu-
sion approach was used [10–14] with vasodilation
induced by adenosine (dipyridamole was used in one
center; n = 10). Patients were classified as ischemia-
positive, if ≥1 segment was ischemic by visual reading
(using a 16-segment model) [26].
Costs of the different procedures and strategies
The analysis was performed from a health care payer
perspective using 2014 unit costs data in Euros (€) for
Germany, in pounds (£) for the United Kingdom, in
Swiss Francs (CHF) for Switzerland, and in US Dollars
(US$) for the United States (for details on health care
systems, see reference [19]). We used reimbursement
rates (tariffs) to assess the costs of procedures. See
Additional file 2 for details on the sources of informa-
tion used to derive the costs of the different tests in
every country.
The average costs per patient for the 3 strategies were
calculated by multiplying the proportion of patients in
the different branches of the diagram (Figs 1, 2 and 3)
with the unit costs of the different tests, revasculariza-
tions, and/or treatments of complications (Table B1 in
Additional file 2).
In patients with revascularizations, the costs of one-
year treatment with clopidogrel and aspirin were
included. By contrast, costs of drugs associated with the
management of risk factors were not taken into account,
as risk factors should be treated in all patients
Fig. 2 The CXA + FRR guided strategy. A hypothetical invasive CXA + FFR strategy is applied to the patients of the European CMR Registry
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irrespective of the presence or absence of ischemia. Fi-
nally, death was not associated with any costs. Given the
time horizon of the analysis of 12 months, no discount
rate was applied.
Sensitivity analysis
To assess the influence of various cost parameters on
the results, one-way deterministic sensitivity analyses
were performed where input parameters were varied one
at a time while the remaining values were held at their
baseline values. Thus, the model was re-run with
changes in the costs of the diagnostic tests of CMR,
FFR, and CXA. As the CMR + CXA strategy and the
CXA + FFR strategy were assumed to yield the same
proportion of ischemia-positive patients, the revasculari-
zation procedures would not differ for the 2 arms. Ac-
cordingly, costs for treatment were not varied. As costs
for the various tests may differ considerably in various
geographical regions of the 4 countries and as costs for
FFR testing are not (yet) well defined in all 4 health care
systems, a break-even analysis was also performed to il-
lustrate the magnitude of reimbursement changes
needed to result in equal costs for the 3 strategies.
Statistics
Categorical data are reported as frequencies and con-
tinuous data as mean ± SD. Differences between patient
groups were assessed using one-way ANOVA and Chi-
square statistics where appropriate (Table 1). A p-value
<0.05 was considered statistically significant.
Results
Demographics
Based on CMR testing, 20.9 % of patients were diag-
nosed with ischemia and 17.4 % of these patients were
revascularized (72.7 % by PCI, 23.5 % by CABG, and
3.8 % underwent both, PCI and CABG). Additionally,
3.3 % of the CMR-negative patients were revascularized.
In the sub-group of patients with typical angina, ische-
mia was diagnosed by CMR in 34.9 % and revasculariza-
tions were performed in 23.2 % of these patients. For
outcomes, see Table 1. During the CMR examination, no
major complications occurred (for details, see Additional
file 3, Table C).
Cost analysis
The average costs per patient for the 3 strategies in the
4 countries with all diagnostic tests (CMR and CXA
with/without FFR) performed as outpatient procedures
are given in Table 2. The cost reductions by the CMR +
CXA strategy in the 4 countries are summarized in
Fig. 4a. Costs reductions of CMR + CXA vs CXA + FFR
were highest in the UK (34 %) and lowest in Germany
(14 %), with US and Switzerland positioned in between
with reductions of 24 % and 27 %, respectively.
As expected, in the study population with typical an-
gina, the rate of revascularizations was higher than in
the total population (Table 1). Also, in the population
with typical angina, the CMR + CXA approach yielded
lower cost savings vs the CXA + FFR strategy ranging
from 2.3 % for Germany to 18.9 % for UK and with cost
savings for US and Switzerland in between with 11.6 %
and 12.8 %, respectively (see Table 2 and Fig. 4b). Cost
savings in the population with atypical chest pain symp-
toms were comparable to the entire study population
(see Table 2 and Fig. 4b).
Inclusion or exclusion of costs for rehabilitation after a
non-fatal MI (for Germany and Switzerland) or of costs
for a visit to see a cardiologist in the first year after re-
vascularization (for Germany, Switzerland, and US) did
not significantly influence the differences between strat-
egies (difference of <1 percentage point, Table 2).
Sensitivity analysis
Results of the sensitivity analyses are given in the
Additional file 4 (Tables D1-D4). Generally, a 10 %
Fig. 3 The CXA-only strategy. With this hypothetical strategy, anatomy as defined by invasive x-ray coronary angiography is the only test for
decision making, no ischemia testing is used. Revascularizations are performed in patients with ≥50 % coronary stenosis
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change in the costs of a diagnostic test (changes intro-
duced into the model one by one) leads to variations
ranging from 1 % to 8 % in final costs of the 3 strategies.
A 10 % increase in the CMR costs leads to a reduction
of 0.7 to 4.3 percentage points on the cost savings of the
CMR + CXA strategy vs CXA + FFR in the 4 health care
systems. A 10 % decrease in the CXA costs would re-
duce the cost savings of the CMR + CXA strategy vs
CXA + FFR by 2.4 to 4.5 percentage points.
When varying the proportion of patients which
undergo FFR in the CXA + FFR strategy from 30 % to
55 %, the sensitivity analysis yields changes in costs in
Table 1 Baseline characteristics
Total population Atypical chest pain Typical angina p-values a
Demographics
n (%) 3’647 (100 %) 1’786 (49.0 %) 582 (16.0 %) -
Male (%)† 58.7 % 45.7 % 42.8 % <0.001
Age at baseline (y); mean (range) ‡ 61.6 (14–92) 61.1 (14–92) 62.6 (26–88) <0.05
Weight (kg); mean (range) § 80.4 (28–183) 80.2 (30–183) 79.7 (28–182) ns
Risk profile
Hypertension § ns
- none 38.1 % 39.1 % 35.4 %
- treated 58.1 % 56.7 % 60.3 %
- untreated 3.9 % 4.3 % 4.3 %
Dyslipidemia ǁ 42.2 % 40.5 % 45.9 % 0.059
Diabetes mellitus ǁ 13.3 % 10.8 % 15.0 % <0.001
Smoker ǁ ns
- No 74.5 % 73.9 % 73.9 %
- Current 12.9 % 12.9 % 13.8 %
- Previous 12.7 % 13.2 % 12.4 %
Family history of CAD § 27.0 % 28.3 % 29.4 % <0.05
Reasons for CAD work-up
- Patient complaints 72.7 % 89.7 % 89.7 % <0.001
- Presence of cardiovascular risk factors 55.9 % 53.4 % 53.1 % <0.001
- Ambiguous Stress ECG 20.2 % 17.4 % 14.4 % <0.001
- Ambiguous Stress Echocardiography 1.9 % 1.4 % 1.2 % <0.01
- Ambiguous Stress SPECT 0.3 % 0.2 % 0.5 % ns
- Ambiguous Cardiac CT 0.9 % 0.7 % 0.5 % ns
Treatment: n (%)
Revascularizations 226 (6.2 %) 81 (4.5 %) 75 (12.9 %) <0.001
- PCI only 179 (4.9 %) 70 (3.9 %) 53 (9.1 %) <0.001
- CABG only 41 (1.1 %) 10 (0.6 %) 19 (3.3 %) <0.001
- PCI and CABG 6 (0.2 %) 1 (0.1 %) 3 (0.5 %) 0.059
Outcome (complications): n (%)
Primary endpoint 75 (2.1 %) 33 (1.9 %) 11 (1.9 %) ns
- Mortality : all cause 34 (0.9 %) 15 (0.8 %) 7 (1.2 %) ns
- Cardiac death 7 (0.2 %) 6 (0.4 %) 0 (0.0 %) ns
- Cardiac death and unknown cause 23 (0.6 %) 13 (0.7 %) 2 (0.3 %) ns
- Non-fatal myocardial infarction 11 (0.3 %) 5 (0.2 %) 2 (0.3 %) ns
- Aborted sudden cardiac death 8 (0.3 %) 4 (0.2 %) 1 (0.2 %) ns
- Stroke 18 (0.5 %) 10 (0.6 %) 1 (0.2 %) ns
a Differences for age and weight were assessed by one-way ANOVA and for the other parameters by the Chi-square statistic. P-values >0.10 are reported as ns.
Reasons for CAD work-up may add up to >100 % as several reasons per patient may apply. † n = 3’643; ‡ n = 3’646; § n = 3’642; ǁ n = 3’641
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favor of the CMR + CXA strategy for all health care sys-
tems and all populations studied with the only exception
for the patients with typical angina in the German
system, where costs savings were minor ranging from
0.8 % to 6.1 % (Additional file 4, Tables D1-D4).
Discussion
Cost minimization by the CMR-guided strategy to manage
patients with suspected CAD
Our study represents an effort of cost-benefits analysis
across systems from 4 countries extrapolated from “real-
world” multinational data from the European CMR registry.
Using the CMR+CXA strategy cost savings ranging from
14 % to 34 % can be expected compared to an invasive
CXA+ FFR strategy when applied on a population of low
to intermediate prevalence of disease. By the same token,
substantial cost savings ranging from 19 % to 38 % can be
anticipated in the patients with atypical chest pain. How-
ever, in the population with typical angina, cost savings
were minimal in the German health care system and only
moderate in the US and Swiss systems with 12 %-13 %,
while they remained substantial in the UK with 19 % cost
Table 2 Costs of the 3 strategies per health care system (n = 3’647)
Costs
CMR + CXA
Costs
CXA + FFR
Costs
CXA-only
% Cost reduction of
CMR + CXA versus
CXA + FFR
% Cost reduction of
CMR + CXA versus
CXA-only
% Cost reduction of
CXA + FFR versus
CXA-only
German context (€)
Main analysis (n = 3'647) 932 1'090 2'298 14.5 59.4 52.6
Main analysis (n = 3'647) without rehab. &
without cardiologist's visit
919 1'082 2'290 15.1 59.9 52.8
- Atypical chest pain (n = 1'786) 787 971 1'990 19.0 60.5 51.2
- Atypical chest pain (n = 1'786) without
rehab. & without cardiologist's visit
780 966 1'985 19.3 60.7 51.3
- Typical angina pectoris (n = 582) 1'466 1'500 2'690 2.3 45.5 44.2
- Typical angina pectoris (n = 582) without
rehab. & without cardiologist's visit
1'456 1'514 2'704 3.8 46.2 44.0
UK context (£)
Main analysis (n = 3'647) 1'075 1'623 2'224 33.8 51.7 27.0
- Atypical chest pain (n = 1'786) 968 1'552 2'052 37.6 52.8 24.4
- Typical angina pectoris (n = 582) 1'513 1'866 2'444 18.9 38.1 23.7
Swiss context (CHF)
Main analysis (n = 3'647) 3'252 4'451 8'399 26.9 61.3 47.0
Main analysis (n = 3'647) without rehab. &
without cardiologist's visit
3'191 4'420 8'368 27.8 61.9 47.2
- Atypical chest pain (n = 1'786) 2'783 4'044 7'520 31.2 63.0 46.2
- Atypical chest pain (n = 1'786) without
rehab. & without cardiologist's visit
2'733 4'017 7'493 32.0 63.5 46.4
- Typical angina pectoris (n = 582) 5'074 5'816 9'511 12.8 46.7 38.9
- Typical angina pectoris (n = 582) without
rehab. & without cardiologist's visit
4'983 5'784 9'479 13.8 47.4 39.0
US context ($)
Main analysis (n = 3'647) 1'740 2'292 6'022 24.1 71.1 61.9
Main analysis (n = 3'647) with cardiologist's
visit
1'759 2'294 6'024 23.3 70.8 61.9
- Atypical chest pain (n = 1'786) 1'429 1'996 5'588 28.4 74.4 64.3
- Atypical chest pain (n = 1'786) with
cardiologist's visit
1'444 1'997 5'589 27.7 74.2 64.3
- Typical angina pectoris (n = 582) 2'947 3'335 6'592 11.6 55.3 49.4
- Typical angina pectoris (n = 582) with
cardiologist's visit
2'983 3'336 6'593 10.6 54.8 49.4
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savings. This sub-population analysis underscores the im-
portance of pre-test probabilities when searching for the
most cost-effective work-up strategy. Thus, in a low pre-
test probability population, which dominates those referred
to non-invasive testing, cost savings might be substantial
with a CMR+CXA strategy, even if the costs of an invasive
CXA is added to all patients with a positive CMR. With an
increasing pre-test probability, as e.g. in the typical angina
population, substantial cost savings may persist in some
countries but may decline in others.
The potential cost savings were observed if all interven-
tions were calculated as out-patient procedures and by tak-
ing into account the costs for revascularizations and
complications during the first year after PCI and/or CABG.
This favorable cost profile of the CMR-based strategy in a
population with low to intermediate disease prevalence is
in line with a cost-effectiveness analysis performed in the
setting of the CE-MARC trial [27]. CMR as a first line test
followed by CXA in patients with a positive or inconclusive
CMR study was found cost-effective in this population at
the higher end of the National Institute for Health and
Clinical Excellence (NICE) threshold range [27]. Of note,
the European CMR registry data are collected from a
network of 59 centers representing 18 countries and are
therefore highly likely to reflect broad CMR performance
achievable in current routine cardiology practice. This
study design also accounted for costs of mis-classifications
(i.e. for false negative CMR studies), as costs of invasive
tests, revascularizations, and costs for complication man-
agement in CMR-negative patients (=false negatives) were
added to the overall costs of the CMR+CXA strategy.
Interestingly, European and US guidelines recommend to
consider CXA as a first test, if the annual mortality is
relatively high, i.e. ≥1 % [5], and/or if results of
Fig. 4 Percentage of cost reductions of the CMR + CXA strategy in comparison to the CXA + FFR and CXA-only strategies for the German, UK,
Swiss, and US health care systems. 4a Cost reductions for the CMR + CXA strategy in the entire study population of 3’647 patients. 4b Cost
reductions for the CMR + CXA strategy in the subgroups of patients with atypical chest pain (n = 1’786) and with typical angina (n = 582)
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noninvasive testing (exclusive of stress imaging) indi-
cate a high likelihood of CAD (as e.g. in long-standing
diabetes or in patients with electrocardiography with dif-
fuse ischemic changes in multiple territories) [9]. The pre-
sented results indicate, that current guidelines on invasive
CXA utilization in stable CAD [5, 9] are also valid when
economic aspects are taken into account as cost savings of
the CMR +CXA strategy were relatively small (or almost
absent) in the studied population with typical angina
and an annual mortality >1 %.
If the CMR+CXA strategy is compared with a CXA-
only strategy, cost savings can be as high as 52–71 %, most
likely due to the fact that ischemia testing reduces the need
for revascularizations. Similar results have been shown in
the past in prospective trials comparing a combined CXA
and FFR approach vs a CXA-only approach [8, 28]. In a
simulation, Moschetti et al. included the FFR ischemia test-
ing in the model and showed that a CMR-based strategy
was more cost-effective than CXA combined with FFR
when applied to a population of low to intermediate pretest
likelihood of CAD [19]. The results of the current study de-
rived from a real patient population with an ischemia
prevalence of 21 % now confirm these model simulations
of Moschetti [19], which predicted cost-effectiveness in the
German, UK, Swiss, and US health care systems in popula-
tions with an ischemia prevalence below 62 % to 83 %.
The European CMR registry design requires indica-
tions for CMR to be in accordance with appropriate use
criteria established by recognized professional organiza-
tions [26, 29]. Interestingly, the prevalence of ischemia on
stress perfusion CMR in a population fulfilling the appro-
priate use criteria was 18.8 % (vs 4.8 % in the rarely appro-
priate group) [30], which is close to the prevalence of
20.9 % in the current study. This finding may indirectly
support the notion that indications in the registry were
following current appropriate use criteria in most cases.
Prognostic power of stress perfusion CMR in a real-world
multi-center setting
Since false negative tests are likely to decrease quality of
life and to increase costs by the management of compli-
cations of unrecognized disease, it is important to assess
the prognostic performance of non-invasive methods. In
this large unselected patient population with suspected
CAD, a normal perfusion-CMR predicted an excellent
outcome with an annual event rate for cardiac death and
non-fatal MI of 0.38 %, which increased to 1.11 %, if
deaths of unknown cause and aborted SCD were added.
These registry outcome data match well with previous
prospective CMR single center studies reporting annual
event rates of cardiac death and non-fatal MI in
ischemia-negative patients of 0.7 % per year [23, 25].
In the CMR negative patients revascularizations oc-
curred in 3.3 % and in the sub-group with typical angina,
they occurred in 7.4 %, which might represent false
negative CMR examinations. However, no FFR proof
was required to guide these revascularizations of CMR
negative patients. In addition, in the FFR-negative popu-
lation of FAME 2, a similar revascularization rate was
observed with 12.0 % over 2 years [22]. It might be spec-
ulated that progression of disease over 1 year post-
testing in ischemia-negative patients could partly
account for these revascularizations. On the other hand,
only 17.4 % of the CMR-positive patients were revascu-
larized and only 23.2 % of the patients with typical an-
gina. This is most likely explained by the fact, that
patients by definition were categorized as “ischemic”
with at least one segment positive on CMR [26], while it
is recommended to revascularize patients with 2 or more
ischemic segments [5].
Limitations
The costs in the 2 invasive strategies were calculated
based on the relationship between the stenosis degree
and FFR-positive findings as reported in the literature
[18, 19]. This relationship was not verified in the study
population. Sensitivity analyses, however, demonstrated
cost savings for the CMR + CXA strategy even when this
relationship was modified. The fact that the invasive
strategies were modeled in this study is certainly a limi-
tation and the 3 different strategies should be assessed
in future prospective randomized cost-effectiveness tri-
als. We believe that this study still yields useful results
as it is based on real-world data in a patient population
of low to intermediate disease prevalence.
In patients with confirmed ischemia, the treatment of
symptoms might be more aggressive and consequently
more costly. This situation, however, would equally affect
costs in the CMR +CXA and CXA+ FFR arm. The know-
ledge of anatomical stenoses could also lead to more ag-
gressive treatment of symptoms and higher costs in the
invasive groups. These potential mechanisms could not be
taken into account in the current study and could cause
underestimations of costs for the invasive strategies.
The registry structure did not allow collecting data to
ensure that patients received optimum medical treatment
before revascularizations as is recommended by guidelines
[5–7, 9, 31] which could influence the outcome. As the
outcomes of the CMR +CXA and CXA+ FFR strategies
were assumed to match, this aspect would not affect the
difference of calculated costs for the two strategies. Also,
in a recent cost-effectiveness model, for CMR (followed
by invasive CXA) and for invasive CXA (including FFR)
the quality-adjusted life years gained varied by only 0.08 %
(for both, the UK and US systems), while costs varied by
4.7 % and 9.2 %, respectively, in favor of CMR [32].
In general, assigning costs to the various procedures
and to hospital stays is a demanding task as some tariff
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systems are heterogeneous and in addition, differences
between geographical regions within a system also exist.
This fact has to be considered when interpreting the
study results. Costs for FFR were not coded in all tariff
systems and therefore, the costs for FFR were calculated
as the difference between two tariff positions (for
Germany, UK, and Switzerland) or by estimating costs
for material [8] and physician payment [33] (for the US).
A low reimbursement of this FFR position could disad-
vantage the CXA-only approach. However, the break-
even analysis indicates, that a 6–12 fold increase in the
FFR reimbursement would be required to match the
costs of the CXA-only strategy.
The CMR + CXA strategy was not compared with
other non-invasive imaging stress tests. This aspect war-
rants testing in future studies.
Conclusions
A CMR +CXA-guided strategy to manage patients with
suspected CAD is less costly than an invasive CXA +
FFR strategy when applied in a real-world patient popu-
lation of low to intermediate prevalence of disease and
when assuming same outcomes for the strategies. This
finding was observed for the German, UK, Swiss, and
US health care systems. However, in the subgroup of pa-
tients with typical angina, cost savings were only min-
imal to moderate. The costs of tests, but also the patient
characteristics represent important factors that deter-
mine the cost-effectiveness of various work-up strategies.
These findings warrant further confirmation in prospect-
ive cost-effectiveness trials.
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